Opinion

Video

Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

Video content above is prompted by the following questions:

  • Did safety outcomes with combination therapy vary from those observed with monotherapy cretostimogene or pembrolizumab?
  • Can you please talk about the duration of response and how this compares to other agents that have been tested in BCG UR CIS +/- papillary disease?
Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
April 17th 2025

Exploring new avenues in non–muscle invasive bladder cancer treatment

Urology Times staff
Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
© 2025 MJH Life Sciences

All rights reserved.